Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

[Guest guest]

Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

Wed Oct 28, 2009 4:05pm EDT

http://www.reuters.com/article/pressRelease/idUS230540+28-Oct-2009+PRN20091028

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.

(Nasdaq: ANDS) announced today that it will present at the Oppenheimer 20th

Annual Healthcare Conference on Wednesday, November 4, 2009 at 4:30 p.m. EST

(1:30 p.m. PST). The conference is being held at the Waldorf Astoria in New

York. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys,

will provide an overview of Anadys and its clinical development programs,

ANA598 and ANA773.

The corporate presentation will be simultaneously webcast and can be accessed

on the Investor Relations page of the Company's website at

www.anadyspharma.com. Listeners are encouraged to visit the website

approximately five minutes prior to the corporate presentation to download or

install any necessary software. A replay of the presentation will be

available approximately one hour after the live webcast concludes and will be

available through November 18, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to

improving patient care by developing novel medicines for the treatment of

hepatitis C. The Company believes hepatitis C represents a large unmet

medical need in which meaningful improvements in treatment outcomes may be

attainable with the introduction of new medicines. The Company is developing

ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis

C. The Company has also investigated the potential of ANA773, an oral,

small-molecule inducer of endogenous interferons that acts via the Toll-like

receptor 7, or TLR7, pathway in hepatitis C.